NDA 009866 · Pharmacia and Upjohn
Solu-Cortef
Hydrocortisone Sodium Succinate · Injection
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1955
Apr 27, 1955
Approved uses
1
Original approval plus efficacy supplements
Registered trials
753
149 Phase 3, 82 recruiting
FAERS reports
9,514
8,627 serious, 2,440 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases:...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 27, 1955 Original approval · Type 2 - New Active Ingredient
4 products under this application
- SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
- SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 100MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
- SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 250MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Platform of Randomized Adaptive Clinical Trials in Critical IllnessPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT05440851 · 6,250 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 31, 2027
Drug: Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose and 6 more · For: Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 103 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic ShockPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01448109 · 3,800 participants · Start Jun 13, 2012 · Primary completion Oct 22, 2017
Drug: Hydrocortisone; Sterile air filled vial · For: Septic Shock
Sites: Blacktown, Australia; Camperdown, Australia; Darlinghurst, Australia · 70 sites in all
Helen FoundationAcademic, hospital or other
NCT03558971 · 2,430 participants · Start Jan 1, 2000 · Primary completion Dec 31, 2016
Drug: Cortisol · For: Rheumatic Diseases
Sites: Apache Junction, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,694
- infusion related reaction1,275
- pyrexia1,136
- fatigue1,130
- dyspnoea1,011
- nausea1,001
- rash974
- pain955
- headache945
- diarrhoea930
- vomiting922
- condition aggravated918
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 109 |
| 2005 | 138 |
| 2006 | 106 |
| 2007 | 180 |
| 2008 | 183 |
| 2009 | 215 |
| 2010 | 269 |
| 2011 | 380 |
| 2012 | 356 |
| 2013 | 248 |
| 2014 | 307 |
| 2015 | 377 |
| 2016 | 389 |
| 2017 | 311 |
| 2018 | 396 |
| 2019 | 509 |
| 2020 | 518 |
| 2021 | 497 |
| 2022 | 718 |
| 2023 | 815 |
| 2024 | 970 |
| 2025 | 996 |
| 2026 | 527 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Solu-Cortef (Hydrocortisone Sod Succinate)
2024 spending
$123K
Beneficiaries
1,221
1,790 claims
Per beneficiary
$101
$12.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $133,432 |
| 2021 | $112,492 |
| 2022 | $134,808 |
| 2023 | $118,982 |
| 2024 | $123,492 |
Part D: Solu-Cortef (Hydrocortisone Sodium Succ/PF)
2024 spending
$990K
Beneficiaries
7,708
13,384 claims
Per beneficiary
$128
$13.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $540,590 |
| 2021 | $623,211 |
| 2022 | $715,904 |
| 2023 | $674,413 |
| 2024 | $989,905 |
Part B: Solu-Cortef* (HydrocortIsone Sod Succinate*) · HCPCS J1720
2024 spending
$480K
Beneficiaries
7,252
24,926 claims
Per beneficiary
$66
2024 ASP limit $18.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $590,909 |
| 2021 | $642,328 |
| 2022 | $680,268 |
| 2023 | $441,127 |
| 2024 | $480,303 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hydrocortisone in Severe Community-Acquired Pneumonia.
Dequin PF, Meziani F, Quenot JP, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
Angus DC · Intensive Care Med 2025 · Randomized Controlled Trial, Multicenter Study
- Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Teja B, Berube M, Pereira TV, et al. · Am J Respir Crit Care Med 2024 · Systematic Review, Comparative Study
- Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Cheema HA, Musheer A, Ejaz A, et al. · J Crit Care 2024 · Meta-Analysis, Systematic Review
- Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.
Annane D, Renault A, Brun-Buisson C, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.
Venkatesh B, Finfer S, Cohen J, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.